William Jacot

44PUBLICATIONS
183CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Clinical midwiferyCancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birth
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Jun 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

|Feb 13, 2026
Neoadjuvant Pembrolizumab Associated with Chemotherapy in Early Triple-Negative Breast Cancer Patients: Real-World Data from a French Single-Center Experience.

Ichrak Ben Abdallah, Severine Guiu, Xavier Quantin

|Dec 10, 2025
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin

|Oct 08, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata

|Sep 29, 2025
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.

Jose Luis Sandoval, Nicolas Kiavue, Lounes Djerroudi

|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

Naoto T Ueno, Francesco Cottone, Kyle Dunton

Pageof 8

Frequent Collaborators

7 joint publications

Caroline Mollevi

6 joint publications

Florence Boissière-Michot

5 joint publications

Luc Cabel

4 joint publications

Jean-Yves Pierga